about us  |  leadership  |  team  |  board of directors  |  scientific advisors

Founded in 2015 by experts in the field of recombinant protein based immunotherapies and a team responsible for the FDA’s approval of the world’s first cancer immunotherapy. Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune/inflammatory disorders, and other diseases.

Mitchell H. Gold, MD

Executive Chairman & CEO

Mark Litton, PhD

President & Chief Operating Officer

Stanford Peng, MD PhD

Executive VP of R&D, Chief Medical Officer

Kristine Swiderek, PhD

Senior VP of Research

Paul Rickey

Chief Financial Officer